Not provided
Not provided
Not provided
Not provided
Not provided
Difficulty accruing patients; business decision
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective, multi center, single arm, clinical study to obtain clinical experience with the use of SERIĀ® Surgical Scaffold for soft tissue support in ventral hernia repair.
Prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device. Subjects will be followed for 24 months post SERI placement during index hernia repair surgery. Study visits will occur at screening, from SERI implantation through hospital discharge and then post SERI implantation at month(s) 1, 3, 6, 12, 18, and 24 for all enrolled subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SERIĀ® Surgical Scaffold | Experimental | It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Silk surgical mesh | Device | A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of Hernia Recurrence | Hernia recurrence at 6 months post-operatively will be assessed by the Investigator and then confirmed via an independent physician. | 6 months postoperatively |
| Rate of Hernia Recurrence | Hernia recurrence at 12 months post-operatively will be assessed by the Investigator and then confirmed via an independent physician. | 12 months postoperatively |
| Rate of Hernia Recurrence | Hernia recurrence at 24 months post-operatively will be assessed by the Investigator and then confirmed via an independent physician. | 24 months postoperatively |
Not provided
Not provided
Inclusion Criteria:
The following are requirements for entry into the study. The subject MUST:
1. Be ā„ 18 years of age
2. Be diagnosed with a ventral hernia as defined as:
Midline Ventral Hernia AND
Defect(s) MUST meet the following criteria:
Be eligible for retro-rectus placement of SERI
Have a BMI < 40
Exclusion Criteria:
The following are criteria for exclusion from participating in the study. The subject must
NOT:
1. prophylactic one-time-use administered peri-operatively
2. inhaled general use
3. topical administration
7. Have documented collagen-vascular, connective tissue, bleeding disorders and/or on anticoagulation therapy, with the exception of baby aspirin for one week prior to SERI placement
8. Have documented cancer < 6 months prior to surgery or chemotherapy treatment < 6 months prior to surgery
9. Have documented history of abdominal radiation therapy or is expected to have abdominal radiation therapy during the conduct of this study
10. Have documented history of liver disease and/or renal failure requiring dialysis
11. Have documented history of a previous wound infection at the surgical site or have an active infection at the time of surgery
12. Have had prior surgery with synthetic and/or biologic mesh in the abdominal, chest or pelvic area
13. Have documented allergy to silk
14. Have documented UTI at the time of surgery
15. Have smoked within 6 weeks of surgery and have a positive nicotine test at time of preoperative visit
16. Have a concurrent procedure intra-operatively (with the exception of lysis of abdominal adhesions)
17. Require intra-peritoneal or bridging placement of the soft tissue support device or require component separation at time of surgery
18. Have surgical circumstances that are contraindicated for use of SERI⢠Surgical Scaffold per the supplied package insert
19. Have a concomitant unrelated condition of abdominal/chest wall/skin that would require a surgical intervention during the follow-up period
20. Have documented alcohol and/or substance abuse problem at time of pre-operative visit
21. Be pregnant, lactating, or if of childbearing potential, be unwilling to use contraceptive methods and avoid pregnancy throughout the study
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Allergan Medical | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Kentucky | Lexington | Kentucky | 40536 | United States |
Not provided
| Label | URL |
|---|---|
| More Information | View source |
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | SERIĀ® Surgical Scaffold | It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device. Silk surgical mesh: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | SERIĀ® Surgical Scaffold | It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device. Silk surgical mesh: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Rate of Hernia Recurrence | Hernia recurrence at 6 months post-operatively will be assessed by the Investigator and then confirmed via an independent physician. | Adults between 18 and 70 years of age with SERI for ventral hernia repair | Posted | Count of Participants | Participants | 6 months postoperatively |
|
24 months after the ventral hernia repair procedure
AE definitions consistent with clinicaltrials.gov
Throughout the course of the study, AEs will be monitored and reported in an AE eCRF, including seriousness, severity, relationship to device, and action taken. If AEs occur, the first concern will be the safety of the study participants. The Investigator and the research staff will monitor each subject closely, and, should a complication occur, they will use their medical judgment to do whatever is necessary to treat the problem.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | SERIĀ® Surgical Scaffold | It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device. Silk surgical mesh: A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abcess | Skin and subcutaneous tissue disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pain | Skin and subcutaneous tissue disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Marcio Torre, M.D., M.A., Medical Monitor | Allergan Medical | 805-683-6761 | torre_marcio@allergan.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
| Primary | Rate of Hernia Recurrence | Hernia recurrence at 12 months post-operatively will be assessed by the Investigator and then confirmed via an independent physician. | Adults between 18 and 70 years of age using SERI for ventral hernia repair | Posted | Count of Participants | Participants | 12 months postoperatively |
|
|
|
| Primary | Rate of Hernia Recurrence | Hernia recurrence at 24 months post-operatively will be assessed by the Investigator and then confirmed via an independent physician. | Adults between 18 and 70 years of age with SERI for ventral hernia repair | Posted | Count of Participants | Participants | 24 months postoperatively |
|
|
|
| 0 |
| 1 |
| 1 |
| 1 |
| 1 |
| 1 |
| Fluid Collection | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Abdominal Muscle Spasm | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
Not provided